Table 1.
Demographics and Clinical Characteristics
| Cross-Sectional Study | Longitudinal Study | ||
|---|---|---|---|
| Total Cohort (n=47) | Baseline (n=39) | Last Visit (n=39) | |
| Age (y) | 17.1 ± 3.9 | 17.5 ± 3.7 | 19.7 ± 3.7 |
| Duration of follow-up (mo) | - | - | 26.4 ± 16.8 |
| Range of follow-up (mo) | 8.4–56.4 | ||
| Sex – number (%) | - | - | - |
| Male | 26 (53%) | 20 (51%) | 20 (51%) |
| Female | 21 (47%) | 19 (49%) | 19 (49%) |
| Tanner Stage – number (%) | - | - | - |
| <4 | 15 (33%) | 10 (26%) | 1 (3%) |
| >4 | 31 (67%) | 28 (74%) | 35 (97%) |
| Race – number (%) | - | - | - |
| White | 23 (49%) | 20 (51%) | 20 (51%) |
| Black | 18 (38%) | 14 (36%) | 14 (36%) |
| Mixed race | 3 (6.5%) | 3 (8%) | 3 (8%) |
| Hispanic ethnicity | 1 (2%) | 0 (0%) | 0 (0%) |
| Native American | 2 (4.5%) | 2 (5%) | 2 (5%) |
| HIV Characteristics | |||
| HIV Viral Load <50 copies/mL – no. (%) | 26 (55%) | 22 (56%) | 24 (62%) |
| CD4 T cell count – cells/mm3 | 658 ± 374 | 626 ± 370 | 725 ± 475 |
| CD4 T cell % | 29.5 ± 10.2 | 28.9 ± 10.5 | 30.3 ± 10.3 |
| Current ART use – number (%) | 44 (94%) | 37 (95%) | 37 (95%) |
| Current PI use – number (%) | 40 (85%) | 33 (85%) | 30 (76.9%) |
| Current or past PI use – number (%) | 46 (98%) | 39 (100%) | 39 (100%) |
| Current d4T use – number (%) | 21 (44%) | 17 (44%) | 7 (17.9%) |
| Current or past d4T use – number (%) | 41 (87%) | 35 (90%) | 35 (90%) |
| Current ABC use – number (%) | 4 (9%) | 4 (10%) | 8 (21%) |
| Current or past ABC use – number (%) | 13 (28%) | 10 (26%) | 18 (46%) |
| Current TDF use – number (%) | 9 (19%) | 7 (18%) | 13 (33%) |
| Current or past TDF use – number (%) | 15 (32%) | 12 (31%) | 20 (51%) |
Note. Data are mean ± standard deviation, except as indicated.